ELSEVIER

Subject Index

A

Acantholytic disorders, inherited, 700–714
Acne
  laser treatment of, 700–714
  unapproved treatments for, 679–688
Acquired immunodeficiency syndrome, skin manifestations in children, 74–86
Acral pigmented skin lesions, 279–285
Acrodermatitis, cutaneous manifestation in infants and children, 51–66
Acyclovir, 474–480
Adrenal diseases, cutaneous manifestation in infants and children, 51–66
Advanced Dermatologic Therapy II (Shelley and Shelley) (book review), 97–98
Adverse drug reactions, 672–678
AIDS, skin manifestations in children, 74–86
Allergy, drug, 29–35
Alternative medicine, 456–460
Anogenital lesions, 668–671
Anthrax, 365–375
  historical perspective on, 336–342
Antibiotics, prophylactic, 396–400
Antifungal drugs, 481–489
Anti-TNF therapy, 522–530
Antiviral drugs, 474–480
Argentina, leprosy in, 187–188
An Atlas of Histopathology of Skin Diseases: An Illustrated Textbook and Reference for Clinicians (Shum and Guenther, et al.) (book review), 190
Austria, Southeastern, 183–186
Automated diagnosis of pigmented skin lesions, 309–312

B

Bacterial skin infections
  biological warfare, 346–354
  unapproved treatments for, 613–617
Balneotherapy, 602–606
Basal cell carcinoma
  laser treatment of, 700–714
  pigmented, 268–269
Biofeedback, 595–601
Biological warfare
  anthrax, 336–342
  bacteria and toxins, 346–354
  coping with, 343–345
  viruses, 355–364
Bites, spider, 618–625
Book reviews
  Advanced Dermatologic Therapy II (Shelley and Shelley), 97–98
  An Atlas of Histopathology of Skin Diseases: An Illustrated Textbook and Reference for Clinicians (Shum and Guenther, et al.), 190
  Comprehensive Dermatologic Drug Therapy (Wolverton), 97–98
  Sclerotherapy Treatment for Varicose and Telangiectatic Leg Veins (Goldman and Berga), 315–316
  Tropical Dermatology (Arenas and Estrada), 97
Bowen's disease, 700–714
Brazil, leishmaniasis in, 122–134
Bullous drug reactions, severe, 672–678
Burns, war, 388–395

C

Carbuncles, 613–617
Cellulitis/erysipelas, 613–617
Children
  cutaneous manifestation of internal diseases in, 51–66
  disorders of hair in, 16–28
  disorders of pigmentation in, 4–10
  mucocutaneous manifestations of viral diseases in, 67–73
  nevi and cutaneous melanoma in, 44–50
  parasitic infections in, 36–43
  skin manifestations of HIV-1 infection in, 74–86
  vascular reactions in, 11–15
Chlamydia trachomatis, 164–169
Cidofovir, 474–480
Clark's nevi, 255–258
Collagen vascular diseases, cutaneous manifestation in infants and children, 51–66
Complementary and alternative medicine, 456–460
  in dermatology, 602–606
  psychotherapy, 595–601
Comprehensive Dermatologic Drug Therapy (Wolverton) (book review), 97–98
Congenital nevi, 263–267
Congress reports
  "Ethnic Hair and Skin: What Is the State of the Science?", 321–324
  Second World Congress of the International Academy of Cosmetic Dermatology (IACD), 99–101
  "Skin Changes and the Face," 317–320
Contact dermatitis
  from gas masks, 396–400
  in military personnel, 439–444
Contact sensitizers, 515–521
Coping
  with bioterrorism, 343–345
  with fear of nonconventional threats, 413–419
  with panic, 413–419
Corticosteroids, topical, 490–492
Cosmetic dermatology, 191–194
Coxsackievirus infections, mucocutaneous manifestations in children, 67–73
Croatia, syphilis in, 141–146
Cryosurgery, 563–570
Cutaneous diseases
  of feet
    in military personnel, 445–451
    unapproved treatments for, 689–699
  infections and infestations
    historical perspective on, 109–113
    manifestations of, 103, 104–108
  malignancies, 700–714
  manifestation of internal diseases in infants and children, 51–66
  melanoma, in infants and children, 44–50
  from protective measures, 396–400

D

Demodex folliculorum dermatitis, 135–140
Dermatitis
  contact
    from gas masks, 396–400
    in military personnel, 439–444
  D. folliculorum, 135–140
  perioral, 679–688
  seborrheic, 679–688
Dermatomyositis, cutaneous manifestation in infants and children, 51–66
Dermatophytes, 643–648
Dermatoscopy
  ABCD rule of, 240–247
  for facial pigmented skin lesions, 276–278
Dermatoses of facial skin, 679–688
Dermatozoonoses, in Brazil, 122–134
Dermoscopy, 199
  of acral pigmented skin lesions, 279–285
  alternative melanocytic algorithms for, 240–247
  classification of Clark's nevi, 255–258
  classification of Spitz/Reed nevi, 259–262
  diagnostic
    of melanoma, 236–239
    of seborrheic keratosis, 270–272
    of vascular lesions, 273–275
  digital
    of melanocytic skin lesions, 297–394
    of pigmented skin lesions, 309–312
  pathologic correlations, 228–235
  of pigmented basal cell carcinoma, 268–269
  of pigmented skin lesions, 200–202
  preoperative evaluation of melanoma thickness by, 305–308
Diabetes mellitus, cutaneous manifestation in infants and children, 51–66
Digital dermoscopy

© 2002 by Elsevier Science Inc. All rights reserved.
360 Park Avenue South, New York, NY 10010

0738-081X/02/$–see front matter
PII S0738–081X(02)0024–3

of melanocytic skin lesions, 297–304
of pigmented skin lesions, 309–312
Digital total-body photography, follow-up of melanocytic skin lesions with, 297–304
DNA typing, in male HPV genital infections, 173–178
Dressings, new, 715–723
Drug allergy, pediatric, 29–35
Drug development, 467–473
Drug reactions
adverse, 672–678
bullous, severe, 672–678
Drugs. *see also specific drugs by name*
antifungal, 481–489
antiviral, 474–480
Comprehensive Dermatologic Drug Therapy (Wolverton) (book review), 97–98
immunosuppressive, 505–514
Dyschromias, 700–714
Dyshidrosis, 689–699

E
Ectoparasitic infestations, anogenital, 668–671
Edema, acute hemorrhagic, of infancy, 2–3
Enteropathies, cutaneous manifestation in infants and children, 51–66
Environmental hazards and threats
from ionizing and nuclear radiation, 330–335
skin diseases in military personnel, 420–424
Epiluminescence surface microscopy, 222–227
Erysipelas, 613–617
Erythrasma, 613–617
"Ethnic Hair and Skin: What Is the State of the Science?" (meeting summary), 321–324
Europe, venereology progress in, 119–121

F
Facial pigmented skin lesions, 276–278
Facial skin dermatoses, 679–688
Fasciitis, necrotizing, 613–617
Fear of nonconventional threats, 413–419
Folliculitis, 613–617
Foot diseases
cutaneous
in military personnel, 445–451
unapproved treatments for, 689–699
hyperhidrosis of, 689–699
infections, 689–699
psoriasis of, 689–699
Furuncles, 613–617

G
Gas masks, contact dermatitis from, 396–400
Genital infections, male HPV, 173–178
Genital warts, 668–671
Graft-*versus*-host reaction, 672–678
Granulomatous diseases, 700–714
Griseofulvin, 481–489
Ground Zero dermatology, 452–453
Gulf War syndrome, 401–412

H
Hair, 321–324
Hair cosmetics, 191–194
Hair disorders
in infants and children, 16–28
laser treatment of, 700–714
Head lice, 94–96
Health hazards and threats from ionizing and nuclear radiation, 330–335
Hemangioma, 660–667
Hemorrhagic edema, acute, of infancy, 2–3
Heparin, 547–557
Hepatitis, malignant syphilis with, 156–163
Herpes genitalis, 668–671
Herpesvirus infections, mucocutaneous manifestations in children, 67–73
Histopathology, 190
Historical perspective
on anthrax, 336–342
on cutaneous infections and infestations, 109–113
Human immunodeficiency virus (HIV-1) infection, skin manifestations in children, 74–86
Human papillomavirus (HPV) infection
male genital, 173–178
mucocutaneous manifestations in children, 67–73
Hydrotherapy, 602–606
Hyperhidrosis
of feet, 689–699
unapproved treatments for, 638–642, 689–699
Hypnosis, 595–601

I
IACD. *see* International Academy of Cosmetic Dermatology
Immunosuppressive drugs, 505–514
Immunotherapy, topical, 515–521
Impetigo, 613–617
Infants
acute hemorrhagic edema in, 2–3
cutaneous manifestation of internal diseases in, 51–66
disorders of hair in, 16–28
disorders of pigmentation in, 4–10
molluscum contagiosum in, 170–172
nevi and cutaneous melanoma in, 44–50
parasitic infections in, 36–43
Infections
bacterial
biological warfare, 346–354
unapproved treatments for, 613–617
cutaneous
historical perspective on, 109–113
manifestations of, 103, 104–108
foot, 689–699
HIV-1, skin manifestations in children, 74–86
M. furfur, 179–182
male HPV genital, 173–178
pemphigus and, 114–118
unusual, in military personnel, 425–434
viral, mucocutaneous manifestations in children, 67–73
Infestations
cutaneous
historical perspective on, 109–113
manifestations of, 103
ectoparasitic, 668–671
parasitic
in infants and children, 36–43
unapproved treatments for, 618–625
Inherited acantholytic disorders, 700–714
Insect repellant, side effects of, 396–400
Interferons, 493–504
Internal diseases, cutaneous manifestation in infants and children, 51–66
International Academy of Cosmetic Dermatology (IACD)
news, 194
Second World Congress, 99–101, 194
International congress reports
"Ethnic Hair and Skin: What Is the State of the Science?", 321–324
"Skin Changes and the Face," 317–320
Ionizing radiation
hazards and threats from, 330–335
light, 571–581

K
Keratosis, seborrheic, 270–272
Kwashiorkor, cutaneous manifestation in infants and children, 51–66

L
Lasers, 700–714
Leishmaniasis, in Brazil, 122–134
Leprosy, in Argentina, 187–188
Lesions. *see also* Skin lesions
pigmented, oral, 286–288
pink, 289–296
vascular, 273–275
vasculitic, 700–714
Lice, head, 94–96
Light irradiation, 571–581
Lipoidoproteinosis, cutaneous manifestation in infants and children, 51–66
Lupus erythematosus
chronic, 679–688
cutaneous
laser treatment of, 700–714
manifestation in infants and children, 51–66
Lyme borreliosis, 147–155

M
Malassezia furfur, 179–182
Male genital infections, HPV, 173–178
Malignant syphilis, with hepatitis, 156–163
Medical cosmetology, 191–194
Meeting summaries, "Skin Changes and the Face," 317–320
Melanocytes
ABCD rule of dermatoscopy for, 240–247
alternative algorithms for, 240–247
Menzies scoring method for, 240–247
7-point checklist for, 240–247
Melanocytic nevi, atypical (Clark's), 255–258

Melanocytic skin lesions, 297–304
Melanoma
  clinical simulators of, 212–221
  cutaneous, in infants and children, 44–50
  early detection of, 203–211
  pattern analysis diagnosis of, 236–239
  thickness, preoperative evaluation of, 305–308
Melasma, 649–659, 679–688
Menzies scoring method, 240–247
Microscopy
  epiluminescence surface, 222–227
  polarized-light videomicroscopy, 222–227
  surface, 263–267
Military personnel
  contact dermatitis in, 439–444
  cutaneous diseases from protective measures, 396–400
  cutaneous diseases of feet in, 445–451
  environmental skin diseases in, 420–424
  unusual skin infections in, 425–434
Molluscum contagiosum, 170–172
Mucocutaneous manifestations of viral diseases in children, 67–73
Mycophenolate mofetil, 505–514

N
Nail disorders
  psoriasis, 643–648
  unapproved treatments for, 643–648
Necrotizing fasciitis, 613–617
Neurotropic agents, 582–594
Nevi
  atypical melanocytic (Clark's), 255–258
  congenital, 263–267
  in infants and children, 44–50
  Spitz/Reed, 259–262
Niacin, 547–557
Nonconventional threats, fear of, 413–419
Nuclear radiation, 330–335
Nuclear terrorism, 330–335
Nucleic acid amplification assays for *C. trachomatis*, 164–169

O
Onychomycosis
  toe, 607–609
  unapproved treatments for, 643–648
Oral pigmented lesions, 286–288

P
Palmoplantar pustulosis, 689–699
Panic, coping with, 413–419
Parasitic infestations
  in infants and children, 36–43
  unapproved treatments for, 618–625
Pathology
  An Atlas of Histopathology of Skin Diseases: An Illustrated Textbook and Reference for Clinicians (Shum and Guenther, et al.) (book review), 190
  dermoscopic correlations, 228–235
Pattern analysis diagnosis of melanoma, 236–239
Pediatric dermatology, 1. *see also* Children; Infants
Pediatric drug allergy, 29–35
Pediculosis
  resistance to, 87–92
  unapproved treatments for, 618–625
Pediculosis capitis, 94–96
Pemphigus, infectious agents and, 114–118
Pentoxifylline, 531–546
Perioral dermatitis, 679–688
Pharmaceutical industry, 467–473
Pharmacists, 726–728
Phenylketonuria, cutaneous manifestation in infants and children, 51–66
Photodynamic therapy, 571–581
Photography, digital total-body, 297–304
Photosensitizers, 571–581
Pigmentation disorders
  in infants and children, 4–10
  unapproved treatments for, 649–659
Pigmented basal cell carcinoma, 268–269
Pigmented lesions
  acral, 279–285
  dermoscopy of, 200–202
    digital, 309–312
  epiluminescence surface microscopy of, 222–227
  facial, 276–278
  management of, 200–202
  oral, 286–288
  polarized-light videomicroscopy of, 222–227
Pink lesions, 289–296
Pitted keratolysis, 613–617
Polarized-light videomicroscopy of pigmented skin lesions, 222–227
Polymerase chain reaction, 147–155
Poxvirus infections, mucocutaneous manifestations in children, 67–73
Protective measures, cutaneous diseases from, 396–400
Psoriasis
  of feet, 689–699
  of nails, 643–648
Psychotherapy, complementary, 595–601
Psychotropic agents, 582–594
Purpura, 626–633
Pustulosis, palmoplantar, 689–699

R
Radiation
  ionizing
    hazards and threats from, 330–335
    light, 571–581
  nuclear, 330–335
Rashes, 672–678
Resistance to pediculosis, 87–92
Retrovirus infections, mucocutaneous manifestations in children, 67–73
Ringworm, 183–186
Rosacea, 679–688
Rosacea-related diseases, 135–140

S
Scabies, 618–625
Scleroderma
  cutaneous manifestation in infants and children, 51–66
  unapproved treatments for, 634–637
Sclerotherapy Treatment for Varicose and Telangiectatic Leg Veins (Goldman and Berga) (book review), 315–316
Sclerotic skin conditions, 634–637
Screening programs for *C. trachomatis*, 164–169
Seborrheic dermatitis, 679–688
Seborrheic keratosis, 270–272
September 11, 2001, 452–453
"Skin Changes and the Face" (meeting summary), 317–320
Skin diseases. *see also* Infections; Infestations
  environmental, in military personnel, 420–424
  in war, 435–438
Skin lesions
  melanocytic, 297–304
  pigmented
    acral, 279–285
    automated diagnosis of, 309–312
    dermoscopy of, 200–202
    epiluminescence surface microscopy of, 222–227
    facial, 276–278
    polarized-light videomicroscopy of, 222–227
Skin tumors, vascular patterns in, 248–254
Smallpox, 376–387
Soldiers. *see also* Military personnel
  cutaneous diseases from protective measures, 396–400
Southeastern Austria, tinea capitis in, 183–186
Spider bites, 618–625
Spitz/Reed nevi, 259–262
Squamous cell carcinoma in situ, 700–714
Sulfasalazine, 531–546
Surface microscopy
  congenital nevi features on, 263–267
  epiluminescence, of pigmented skin lesions, 222–227
Surgery
  cryosurgery, 563–570
  preoperative evaluation of melanoma thickness, 305–308
Surgical cosmetology, 191–194
Sweat gland disorders, 638–642
Syphilis
  in Croatia, 141–146
  malignant, with hepatitis, 156–163

T
Tacrolimus, 505–514
Tattoo pigmentation, alteration of, 700–714
Telangiectasia, 315–316
Terrorism
  bioterrorism, 343–345
  Ground Zero dermatology, 452–453
  nuclear, 330–335
Thyropathies, cutaneous manifestation in infants and children, 51–66
Tinea capitis, in Southeastern Austria, 183–186

Tinea pedis, 689–699
Tissue-engineered living skin, 715–723
Toe onychomycosis, 607–609
Topical corticosteroids, 490–492
Topical immunotherapy, 515–521
Topical vitamin D_3 analogues, 558–562
Total-body photography, digital, 297–304
Toxins, biological, 346–354
Tropical Dermatology (Arenas and Estrada) (book review), 97
Tumor necrosis factor, 522–530
Tumors, skin, 248–254

U
Unapproved treatments
  for adverse drug reactions and graft-*versus*-host reaction, 672–678
  for anogenital lesions, 668–671
  for bacterial skin infections, 613–617
  for disorders of pigmentation, 649–659
  for disorders of sweat glands, 638–642
  for facial skin dermatoses, 679–688
  for hemangioma and vascular malformations, 660–667
  lasers, 700–714
  for nail disorders, 643–648
  for parasitic skin infestations, 618–625
  for purpura and vasculitis, 626–633
  for scleroderma and sclerotic skin conditions, 634–637
Unapproved uses, dosages, or indications, 465–466
  for antifungal drugs, 481–489
  for antiviral drugs, 474–480
  for cryosurgery, 563–570
  for immunosuppressive drugs, 505–514
  for interferons, 493–504
  for miscellaneous treatments, 531–546, 547–557
  for photodynamic therapy, 571–581
  for psychotropic and neurotropic agents, 582–594
  for topical corticosteroids, 490–492
  for topical immunotherapy, 515–521
  for topical vitamin D_3 analogues, 558–562
Urticaria, 672–678

V
Vaccinations, adverse reactions to, 396–400
Varicose veins, 315–316
Vascular lesions, 273–275
Vascular malformations, 660–667
Vascular patterns, 248–254
Vascular reactions, in children, 11–15
Vasculitic lesions, 700–714
Vasculitis, 626–633
Venereology, in Europe, 119–121
Verrucae, 689–699
Videomicroscopy, polarized-light, 222–227
Viral diseases
  anogenital, 668–671
  biological warfare, 355–364
  mucocutaneous manifestations in children, 67–73
Vitamin D_3 analogues, topical, 558–562
Vitiligo, 649–659

W
War
  biological, 346–354, 355–364
  gearing up for, 327, 328–329
  skin diseases in, 435–438
War burns, 388–395
Warts, genital, 668–671
World Trade Center (NY), 452–453

Author Index

A
Andreassi L, 309
Argenziano G, 200
Argenziano G, 199, 200, 228, 259
Assmann T, 505

B
Baran R, 191, 193
Baroni A, 286
Basta-Juzbasiç A, 135, 178
Beeching NJ, 365
Benedetto AV, 700
Blaszczyk M, 634
Blum A, 255
Braun RP, 236, 270
Brenner S, 114, 191, 203
Burgdorf WHC, 276
Burroni M, 309

C
Calatayud JC, 194
Cardozo Pereira AL, 679
Carli P, 305
Cauwenbergh G, 467
Cestari TF, 51
Cheung JS, 638
Chimenti S, 200, 259
Christopher GW, 355
Cieslak TJ, 346, 355

D
Dawber R, 563
De Giorgi V, 305
Dell'Eva G, 309
de Moura Castro Jacques C, 679
De Rosa G, 228
Dolev E, 343
Dolianitis C, 94
Du Vivier A, 515

E
Eldad A, 388

F
Faber WR, 2
Farro P, 672
Fatoviç-Ferenciç S, 109
Feldman M, 29
Ferrara G, 228
Ferrari A, 259
Fishman C, 44

G
Gaeta GM, 286
Garbe C, 255
Gatt P, 420
Ginter-Hanselmayer G, 183
Grahovac B, 147
Grce M, 173
Gupta AK, 607

H
Hart CA, 365
Hartstein BH, 346
Higgins E, 515
Hofmann-Wellenhof R, 255
Holubar K, 109
Husar K, 170
Husnjak K, 173

J
Jablonska S, 634
Jacques CMC, 122
Jappe U, 425
Johr RH, 240, 289

K
Katsambas A, 626, 649, 689
Kawalek A, 376
Kerl H, 255
Khandpur S, 481
Kibbi AG, 4, 11
Koo JY, 582
Kopf AW, 236, 270
Kreitler S, 413
Kreusch JF, 248

L
Lagos BR, 490
Lebwohl M, 97, 190, 315
Levanat S, 147
Lewis AT, 700
Lipozenciç J, 103, 104, 141, 173, 178
Ljubojeviç S, 135, 178, 317

M
Maibach HI, 490
Malvehy J, 297
Marinoviç B, 141, 147
Matz E, 435
Matz H, 212, 396, 435, 439, 493, 522, 531, 547, 618
Menzies SW, 268
Messeritsch-Fanta C, 183
Metzker A, 660
Mihm MC Jr, 44
Millikan LE, 29, 602
Miyazaki A, 279
Moraru rheumatoid arthritis, 452

N
Ng TC, 582

O
Obadiah J, 643
Oguchi S, 279
Olivares LM, 187
Oliviero M, 236, 270
Orion E, 212, 396, 435, 439, 493, 522, 531, 547, 618
Ottolini MG, 355
Oumeish I, 36, 401
Oumeish OY, 1, 36, 327, 328, 330, 401, 445
Özdemir M, 668

P
Pace J, 420
Parish JL, 401, 558
Parish LC, 87, 97, 98, 156, 327, 328, 336, 445, 456
Pašiç A, 104
Pellacani G, 222, 263
Peris K, 259
Piccolo D, 255
Poje G, 147
Puig S, 297

R
Rabinovitz HS, 236, 270
Ramos-e-Silva M, 51, 99, 122, 317, 321, 679, 715
Rebora A, 474
Ribeiro de Castro MC, 715
Riga P, 626
Rubegni P, 309
Rubeiz N, 4
Rudikoff D, 376
Ruocco E, 228, 672
Ruocco V, 199, 200, 212, 522, 618, 672
Ruzicka T, 505

S
Sacerdoti G, 672
Sadick NS, 315, 613
Saida T, 279
Saliba EK, 36
Salman SM, 11
Salva KA, 571
Sasson A, 114
Satriano RA, 286
Saurat JH, 236, 270
Saygin A, 668
Scher R, 643
Schiffner R, 276
Sehgal VN, 481
Seidenari S, 222, 263
Shah AA, 190
Sharon O, 114
Shenefelt PD, 595
Sinclair R, 94
Sinclair RD, 16
Sirotkoviæ-Skerlev M, 173
äitum M, 147
Skerlev M, 104, 170, 173, 178
Smitt JHS, 2
Sober AJ, 44
Solomon BA, 638
Soyer HP, 199, 200, 228, 255, 259
Staibano S, 228
Stary A, 164, 183
Stefanaki C, 74, 649, 689
Stolz W, 276
Stone SP, 94, 456
Straten MV, 67
Stratigos AJ, 74
Stratigos JD, 74
äubiç JS, 135

T
Talbot TB, 346
Tamir E, 203
Tanus FH, 51
Tüzün B, 531, 547, 668
Tüzün Y, 531, 547, 668
Tyring SK, 67

V
Van Neste D, 193
Vermeer MH, 2

W
Wade MS, 16
Waugh M, 119
Witkowski JA, 87, 156, 336, 456
Wolf IH, 255, 273
Wolf R, 212, 327, 328, 396, 435, 439, 465, 493, 522, 531, 547, 618, 668, 672

Z
Zabawski EJ Jr, 726
Zalaudek I, 255
Zvulunov A, 660

© 735 by Elsevier Science Inc. All rights reserved.
360 Park Avenue South, New York, NY 10010

0738-081X/02/$–see front matter
PII S0738–081X(02)0024–3